Gland Pharma Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/o9isznlryp067w2wf6syv2pm.pdf

Key Takeaways


Base Business Recovery & US Dynamics

Srinivas Sadu: "Earlier, we were not competitive enough to compete in that space. But because of the shortages, we did get benefit of certain products for sure. But timing-wise, I can't really say how long this will stay."

Cenexi: The Turnaround Math

Srinivas Sadu: "Today, the issue is not orders. We have EUR2 crore to EUR2.5 crore orders of backlog and the consent is the capacity."

Cenexi: The Turnaround Plan

Alain Kirchmeyer: "Clearly, our immediate goal is to bring Cenexi back to profitability and in the medium to long term, deliver high-teen margins."

Complex Injectables & Portfolio Progression

Srinivas Sadu: "And also, the exact situation in the US a lot of funding has stopped. And whenever you have a new asset, especially guys entering the biologic space, you need to work with the smaller development companies where the funding has stopped."

Geographic & Market Updates

MarketTrendCommentary
US (base business)▲ Strong recoveryPricing stabilized (~1% negative YoY); relaunches and new launches drove 15% growth; guided 14–15% annual growth.
China▼ Below expectationsOnly 1 product commercialized with not yet substantial contribution; actively collaborating with Fosun to reassess approach.
Rest of World▲ Growth expectedRecently established businesses anticipated to deliver significant growth over the next 2 to 3 years.
India▬ Under evaluationCurrently evaluating strategic options to develop a well-considered future plan.

Quality & Operational Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
US base business growth14% to 15% annual growth rate, combination of base and new launchesAnnual
Cenexi positive EBITDAAt €5 crore quarterly run rate, should reach positive EBITDA~3 quarters
Cenexi high-teen marginsMid to long-term goal of high-teen EBITDA margins1 to 2 years
Cenexi new line installationInstallation to begin; commercial ramp-up roughly a quarter afterSeptember quarter
Cenexi cost baseLower cost base in actual terms as expansion completes and volume growsA few more quarters
Complex injectablesNext two years crucial for realizing meaningful results2 years
Rest of World marketsSignificant growth anticipated in recently established businesses2 to 3 years

Key Metrics

MetricQ4 FY24
Revenue from operations₹1,537.5 cr, +96% YoY
Revenue excluding Cenexi+50% YoY
Gross margin61%, up from 54% in Q4 FY23
Base business gross margin56%, improved YoY
EBITDA₹358.7 cr, +113% YoY
EBITDA margin23%, up from 21% in Q4 FY23
Base business EBITDA margin37%, up from 21% in Q4 FY23
Net profit (PAT)₹192.4 cr, +145% YoY
PAT margin13%
Consolidated effective tax rate35%, due to absence of deferred tax asset at Cenexi for PBT losses
R&D expenses₹43.6 cr
ANDAs filed4
ANDA approvals received6
Cenexi revenue₹363.7 cr, -18% QoQ
Cenexi gross contribution77%
Cenexi EBITDANegative ₹72 cr
Cenexi order backlog€2 cr to €2.5 cr
Base business US growth guidance14% to 15% annual growth rate
Eribulin addressable market$170 mn to $180 mn
Cash flow from operations (FY24)₹996.8 cr for 12 months ended March 31, 2024
Net working capital₹2,407.4 cr as of March 31, 2024, flat YoY
Cash conversion cycle (FY24)169 days, improved from 256 days in FY23
Capital expenditure (FY24)₹397.5 cr, of which ₹236.8 cr spent on India facilities
Net cash position₹2,175.6 cr as of March 31, 2024
Dividend per share₹20, first dividend post listing